Informations sur le produit
- 3- (Dimethylamino) - N- [3- [(4- hydroxybenzoyl) amino] - 4- methylphenyl] benzamide
- Benzamide, 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]-
- N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide
- Zm 336372
- Zm336372
ZM336372 is a nanoparticulate composition that inhibits angiogenesis by binding to the epidermal growth factor receptor (EGFR). It has been shown in vivo to inhibit tumor development and tumor metastasis in the MCA-2 carcinoid model. This drug also blocks cell signaling pathways, including those involved in cancer cell proliferation. ZM336372 has demonstrated anti-angiogenic effects in vitro using mesenteric microvascular endothelial cells and live animal models. The drug has also been shown to block the activation of NFκB, which induces the production of proinflammatory cytokines and chemokines that are associated with angiogenesis. ZM336372 has been observed to inhibit the growth of renal cell cancer cells and cytosolic protein levels. This drug may have therapeutic properties for the treatment of infectious diseases such as tuberculosis and malaria.